4D Molecular Therapeutics Insider Ashoo Gupta Files Form 4
| Field | Detail |
|---|---|
| Company | Gupta Ashoo |
| Form Type | 4 |
| Filed Date | Mar 24, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-filing, form-4, ownership-change
TL;DR
**Insider Ashoo Gupta at 4D Molecular Therapeutics just filed a Form 4, signaling a change in their stock ownership.**
AI Summary
This Form 4 filing, dated March 24, 2026, indicates a change in beneficial ownership for Ashoo Gupta, an insider at 4D Molecular Therapeutics, Inc. (CIK: 0001650648). While the filing itself doesn't detail the transaction, it signals that an insider's stake in the company has been altered. This matters to investors because insider transactions can sometimes signal management's confidence (or lack thereof) in the company's future prospects, potentially influencing stock price.
Why It Matters
Insider filings like this can provide clues about how company executives view the stock's value, which can be a significant factor for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is purely administrative, reporting a change in ownership, and does not inherently indicate a high risk.
Analyst Insight
A smart investor would monitor subsequent Form 4 filings from Ashoo Gupta to determine if the change in ownership was a buy or sell, and the magnitude, to gauge insider sentiment towards 4D Molecular Therapeutics, Inc. stock.
Key Players & Entities
- Gupta Ashoo (person) — Reporting Person
- 4D Molecular Therapeutics, Inc. (company) — Issuer
- 0002091461 (person) — CIK for Gupta Ashoo
- 0001650648 (company) — CIK for 4D Molecular Therapeutics, Inc.
FAQ
Who is the reporting person in this Form 4 filing?
The reporting person in this Form 4 filing is Gupta Ashoo, with CIK 0002091461.
What company is the issuer associated with this Form 4?
The issuer associated with this Form 4 is 4D Molecular Therapeutics, Inc., with CIK 0001650648.
When was this Form 4 filing accepted by the SEC?
This Form 4 filing was accepted by the SEC on March 24, 2026, at 18:30:41.
What is the business address listed for 4D Molecular Therapeutics, Inc.?
The business address listed for 4D Molecular Therapeutics, Inc. is 5858 HORTON STREET #455 EMERYVILLE CA 94608.
What is the SIC code for 4D Molecular Therapeutics, Inc.?
The SIC code for 4D Molecular Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 8.2 · Accepted 2026-03-24 18:30:41
Filing Documents
- ownership.html (4)
- ownership.xml (4) — 12KB
- 0001193125-26-122341.txt ( ) — 14KB
From the Filing
SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Gupta Ashoo (Last) (First) (Middle) C/O 4D MOLECULAR THERAPEUTICS, INC. 5858 HORTON STREET #455 (Street) EMERYVILLE CALIFORNIA 94608 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol 4D Molecular Therapeutics, Inc. [ FDMT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) VP, Finance and Controller 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/20/2026 M 865 A (1) 47,224 D Common Stock 03/20/2026 S (2) 310 D $ 8.61 46,914 D Common Stock 03/20/2026 M 221 A (1) 47,135 D Common Stock 03/20/2026 S (2) 80 D $ 8.61 47,055 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units (1) 03/20/2026 M 865 (3) (3) Common Stock 865 $ 0 12,119 D Restricted Stock Units (1) 03/20/2026 M 221 (4) (4) Common Stock 221 $ 0 3,087 D Explanation of Responses: 1. Restricted Stock Units convert into common stock on a one-for-one basis. 2. The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. 3. The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. 4. The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. /s/ Scott Bizily as Attorney-in-Fact for Ashoo Gupta 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)